Scribe Therapeutics (SCTX) Stock Price, News & Analysis

Company Overview

Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based genetic medicines. The company’s platform is designed to engineer gene-editing systems with the aim of improving precision, delivery and therapeutic performance for the treatment of serious diseases.

Its research includes engineered CRISPR enzymes, guide RNAs and other components intended for use in both in vivo and ex vivo gene-editing applications. Scribe has pursued programs in areas including genetic and neurological disorders, although the status and scope of individual development programs may change as research advances.

Founded in 2018, Scribe Therapeutics was established by researchers and entrepreneurs associated with the development of CRISPR technologies. The company is based in California and has entered into collaborations with larger life-sciences companies to explore gene-editing medicines. Scribe Therapeutics is a privately held biotechnology company; the provided NASDAQ ticker, SCTX, could not be independently verified as belonging to the company.

Key Stats

• Today's Range: $20.21 to $23.28
• 50-Day Range: $18.06 to $37.25
• 52-Week Range: $17.31 to $39.60
• Volume: 458,390 shs
• Average Volume: 369,705 shs
• Market Capitalization: $402.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $51.75
• Consensus Rating: Moderate Buy

Scribe Therapeutics Stock Analysis - MarketRank™

Scribe Therapeutics scored higher than 77% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Scribe Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Scribe Therapeutics has a consensus price target of $51.75, representing about 143.2% upside from its current price of $21.28.

Amount of Analyst Coverage

Scribe Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Scribe Therapeutics are expected to grow in the coming year, from ($3.68) to ($2.52) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.18% of the float of Scribe Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Scribe Therapeutics has a short interest ratio ("days to cover") of 4.56.

Change versus previous month

Short interest in Scribe Therapeutics has recently increased by 1.59%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scribe Therapeutics does not currently pay a dividend.

Dividend Growth

Scribe Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.49

News Sentiment

Scribe Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Scribe Therapeutics this week, compared to 6 articles on an average week.

Search Interest

7 people have searched for SCTX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Scribe Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of Scribe Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $56,291,746.00 in company stock, which represents 13.9741% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Scribe Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $56,291,746.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

Scribe Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/02/2026
• Today: 9/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SCTX
• CIK: 1853921
• Web: www.scribetx.com
• Phone: (510) 454-0213
• Fax: N/A
• Employees: 89
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Scribe Therapeutics: $51.75
• High Price Target: $60.00
• Low Price Target: $37.00
• Potential Upside/Downside: +143.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,930,000
• Free Float: N/A
• Market Cap: $402.83 million
• Optionable: N/A
• Beta: N/A